癫痫持续状态试验结局期望度排序:一种设计分析临床SE试验的获益-风险方法
多数癫痫持续状态(SE)试验将疗效与危害分开评估,采用二分类主要结局并单独记录不良事件,无法反映患者反应的细微差别及获益与危害的相关性。本文介绍结局期望度排序(DOOR)方法,以患者整体结局的期望度比较不同治疗组,从而在评估疗效时同时考虑患者承受的毒性等代价,并给出将DOOR应用于惊厥性SE临床试验的示例。
要点
- 传统SE试验以二分类疗效指标和独立不良事件评估获益与危害,忽略患者整体结局的层次。
- DOOR按患者整体结局的期望度排序比较治疗组,同时纳入疗效与毒性等患者承受的代价。
- 文中以惊厥性SE临床试验为例说明DOOR方法的潜在应用。
核心结论
- DOOR方法通过比较不同治疗组患者整体结局的期望度,同时考虑个体患者的获益与危害,是一种以患者为中心的临床试验结局评估方法。
研究设计与样本
- 本文为方法学论述,介绍DOOR的原理、有序结局开发与统计分析的相关问题,并给出将DOOR应用于惊厥性SE临床试验的示例;原文未报告样本量。
主要发现
- 传统方法将疗效定义为临床无明显发作且意识恢复,但部分SE病因(如蛛网膜下腔出血或卒中)可能不伴意识恢复,且即使SE成功终止,需插管也可能被归类为治疗失败。
- DOOR方法按整体结局期望度比较:SE成功终止但有大副作用者结局期望度低于成功终止且有轻微副作用者,后者又低于成功终止且无副作用者。
关键数值与推荐
- 原文未报告具体数值阈值或推荐等级。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most clinical trials of treatment efficacy evaluate benefits and harms separately. Investigators generally rate the primary outcome of a trial with a binary outcome measure and consider harms separately as adverse events. This approach fails to recognize finer gradations of patient response, correlations between benefits and harms, and the overall effects on individual patients. For example, in status epilepticus trials, efficacy is often defined as the absence of clinically apparent seizures with recovery of consciousness. Such an efficacy outcome fails to recognize that some causes of status epilepticus, such as subarachnoid hemorrhage or stroke, may not be accompanied by return of consciousness, and the need to intubate a patient may be classified as treatment failure even if status was successfully terminated. The Desirability of Outcome Ranking (DOOR) method uses a different approach. The DOOR method involves comparing the experiences of trial participants in different treatment arms by the desirability of the overall patient outcome. Using status epilepticus treatment as an example, a patient who experiences successful termination of status epilepticus but with major side effects would have a less desirable outcome than a patient with treatment success and minor side effects, who in turn would have a less desirable outcome than a patient with treatment success but no side effects. This is a patient-centered approach because it considers treatment efficacy in the context of the costs borne by the patient, for example, toxicity in achieving efficacy. Thus, DOOR considers both the benefits and harms to individual patients in assessing the outcome of a clinical trial. In this article, we present the rationale for the use of DOOR, the issues involved in the development of and statistical analyses of an ordinal outcome, and an example of the potential application of the DOOR method to a clinical trial of convulsive status epilepticus.
引用
- Chamberlain JM, Kapur J, Silbergleit RS, et al. Desirability of Outcome Ranking for Status Epilepticus: A Benefit-Risk Approach to Design and Analyses of Clinical SE Trials. Neurology. 2023. PMID: 37580166. doi:10.1212/WNL.0000000000207684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。